By Connor Hart Thermo Fisher Scientific is expanding its partnership with Sanofi to enable additional U.S. drug-product manufacturing. Under the expanded partnership, Thermo Fisher will acquire ...

Life sciences and specialty diagnostics giant Thermo Fisher Scientific Inc. (NYSE: TMO) said it has received a $94.5 million contract to supply the U.S. Navy with advanced radiation detection systems, ...

Thermo Fisher Scientific is reportedly planning to divest parts of its diagnostics unit for approximately $4 billion to focus on higher growth assets. This move is expected to impact the financial ...

JHVEPhoto Thermo Fisher Scientific (NYSE: TMO) is looking to sell some of its lower-growth diagnostic assets for around $4B, the Financial Times reported, citing three people familiar with the matter.

(Reuters) -Thermo Fisher Scientific plans to sell its diagnostics unit for about $4 billion in an attempt to offload some of its low-growth assets, the Financial Times reported on Thursday, citing ...

Thermo Fisher Scientific has put part of its diagnostics unit up for sale for about $4bn in the latest move by a life sciences company to attempt to offload some of its low-growth assets.

Thermo Fisher launches the Orbitrap Astral Zoom and Orbitrap Excedion Pro MS at ASMS 2025, advancing proteomics and drug development.

Thermo Fisher introduces next-gen mass spectrometry solutions at ASMS, designed to accelerate research in multiple scientific fields.

Thermo Fisher Scientific, a Massachusetts-based CDMO giant, inked a collaboration deal with biotech startup Mirai Bio to develop and manufacture new gene therapies. The two aim to pair Thermo ...

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

Conclusion Thermo Fisher was priced for perfection in January near $600, and we got a lot of imperfection in the form of slow growth plus tariff and fiscal policy headwinds.